Pfizer's stock rose 2.8% today after RBC Capital Markets upgraded it from "underperform" to "sector perform," removing its sell rating. RBC noted that with the stock down 11% from its highs and offering a 6.7% dividend yield, the price is right, despite concerns about its entry into the GLP-1 weight-loss drug market. The bank sees potential revenue growth from Pfizer's late-stage cancer drugs.

Jefferies Equity Research analysts, led by David Katz, reported mixed sentiments from their recent visit to Las Vegas. While Strip trends were solid due to a strong convention cycle, low-end leisure travel remained unresolved, and economic factors began to depress locals-casino action. Katz remains cautious on overall Strip fundamentals due to uncertain demand signals, but expresses optimism for long-term growth in the core locals market.

InterDigital (IDCC) saw its stock surge 10.5% to $280.68 following the announcement of a patent license agreement with Amazon. This deal, which covers Amazon's services and devices, is a significant win for the intellectual property licensing firm, contributing to heightened trading volume and investor interest. The agreement validates InterDigital's intellectual property and strengthens its recurring revenue streams.

Craig International plans a $200 million renovation of the former Globe Life headquarters in McKinney, transforming the 58-acre campus into a mixed-use development named Rowlett Station. This project will include multifamily, retail, and office components. The article also provides updates on various other commercial real estate deals in the Dallas-Fort Worth area, including office developments, corporate relocations, federal property sales, multifamily acquisitions, and financing rounds.

Oracle's shares dropped over 11% after its fiscal fourth-quarter cloud revenue slightly missed expectations and the company announced plans to raise $40 billion for AI infrastructure expansion. Despite this, major AI and technology ETFs remained largely stable, indicating that investors view Oracle's performance as a company-specific event rather than a broader concern for the AI market. This muted reaction suggests that investors are focusing on long-term indicators of AI demand, such as Oracle's large contract backlog and expanding infrastructure business, rather than short-term revenue fluctuations.

Gilead Sciences' stock (GILD) rose by 3.48% due to positive developments in its pipeline, particularly in HIV treatments. Key drivers include positive Phase 3 results for islatravir/lenacapavir, FDA priority review for bictegravir/lenacapavir, and strong performance in existing HIV products. Additionally, positive Phase 3 results for Livdelzi in primary biliary cholangitis contributed to investor optimism, despite some setbacks in oncology.

Honeywell International's stock is trading higher after the company outlined new financial targets and portfolio actions at its Investor Day, ahead of the planned spin-off of Honeywell Aerospace. The company targets 4% to 6% organic growth, over 10% annual adjusted EPS growth, and more than 90% free cash flow conversion by 2029. Honeywell is also positioning itself as a pure-play global automation business and plans significant investment in its software platform, Honeywell Forge.

Lowe's Companies Inc. has partnered with Live Nation to offer exclusive concert perks to its MyLowe's Rewards and MyLowe’s Pro Rewards loyalty members throughout the summer concert season. These benefits include discounted tickets, complimentary lawn chair rentals, and sweepstakes for free tickets. The partnership also makes Lowe's the first presenting partner of Live Nation's new amphitheater tailgate experience, featuring live entertainment, food, and programming from Lowe's vendor partners.

Ideaya Biosciences (IDYA) has formed a clinical partnership with Roche to study the safety and efficacy of IDE892 in combination with Roche’s pan-RAS inhibitor, RG6505, for patients with MTAP-deleted pancreatic ductal adenocarcinoma. Ideaya will oversee and finance the combination experiment, with Roche providing RG6505. This collaboration follows Ideaya's recent presentation of positive Phase 2/3 data for its skin cancer drug, which cut the risk of disease progression by 58%.

Thermo Fisher Scientific has launched the Gibco CTS Compleo Fill and Finish System, an automated and functionally closed solution designed to improve cell therapy manufacturing. This system addresses the challenges of manual formulation and filling by reducing variability and contamination risk, thereby enhancing efficiency and consistency. Early collaborators, such as Arsenal Biosciences, have reported positive results in streamlining their cell therapy processes with this new technology.